Search

Your search keyword '"Ganem D"' showing total 437 results

Search Constraints

Start Over You searched for: Author "Ganem D" Remove constraint Author: "Ganem D"
437 results on '"Ganem D"'

Search Results

201. Mechanisms governing expression of the v-FLIP gene of Kaposi's sarcoma-associated herpesvirus.

202. Modulation of cellular and viral gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus.

203. The biology of Kaposi's sarcoma.

204. On the control of late gene expression in Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8).

205. Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis.

206. Hepatitis delta virus replication generates complexes of large hepatitis delta antigen and antigenomic RNA that affiliate with and alter nuclear domain 10.

207. Inflammatory cytokines and the reactivation of Kaposi's sarcoma-associated herpesvirus lytic replication.

208. Transcriptional activation by the product of open reading frame 50 of Kaposi's sarcoma-associated herpesvirus is required for lytic viral reactivation in B cells.

209. Evidence for concurrent epidemics of human herpesvirus 8 and human immunodeficiency virus type 1 in US homosexual men: rates, risk factors, and relationship to Kaposi's sarcoma.

210. A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposi's sarcoma-associated herpesvirus.

211. Expression of the open reading frame 74 (G-protein-coupled receptor) gene of Kaposi's sarcoma (KS)-associated herpesvirus: implications for KS pathogenesis.

212. Deregulated signal transduction by the K1 gene product of Kaposi's sarcoma-associated herpesvirus.

213. Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein.

214. Mathematicians turn their attention to hepatitis C.

215. A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus.

216. In vivo effects of mutations in woodchuck hepatitis virus enhancer II.

217. Limited transmission of Kaposi's sarcoma-associated herpesvirus in cultured cells.

218. Sexual transmission and the natural history of human herpesvirus 8 infection.

219. Activation of heterologous gene expression by the large isoform of hepatitis delta antigen.

222. The structure and coding organization of the genomic termini of Kaposi's sarcoma-associated herpesvirus.

223. Absence of detectable human herpesvirus 8 in the semen of human immunodeficiency virus-infected men without Kaposi's sarcoma.

225. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy.

226. Visualization of human herpesvirus type 8 in Kaposi's sarcoma by light and transmission electron microscopy.

227. The prevalence of serum antibody to human herpesvirus 8 (Kaposi sarcoma-associated herpesvirus) among HIV-seropositive and high-risk HIV-seronegative women.

228. Characterization of ribonucleoprotein complexes containing an abundant polyadenylated nuclear RNA encoded by Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8).

229. Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells.

230. The size and conformation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) DNA in infected cells and virions.

231. A cellular homolog of hepatitis delta antigen: implications for viral replication and evolution.

232. A host factor that binds near the termini of hepatitis B virus pregenomic RNA.

233. Evidence for activation of the hepatitis B virus polymerase by binding of its RNA template.

234. Relationship between viral DNA synthesis and virion envelopment in hepatitis B viruses.

235. The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission.

236. Cellular factors controlling the activity of woodchuck hepatitis virus enhancer II.

237. Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma.

238. Homologous and heterologous complementation of HBV and WHV capsid and polymerase functions in RNA encapsidation.

239. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture.

240. Activation of N-myc2 gene expression by cis-acting elements of oncogenic hepadnaviral genomes: key role of enhancer II.

241. Apoptosis is induced by N-myc expression in hepatocytes, a frequent event in hepadnavirus oncogenesis, and is blocked by insulin-like growth factor II.

242. Frequent presence of a novel herpesvirus genome in lesions of human immunodeficiency virus-negative Kaposi's sarcoma.

243. The pre-S domain of the large viral envelope protein determines host range in avian hepatitis B viruses.

244. RNA sequences controlling the initiation and transfer of duck hepatitis B virus minus-strand DNA.

245. gp180, a host cell glycoprotein that binds duck hepatitis B virus particles, is encoded by a member of the carboxypeptidase gene family.

246. AIDS. Viruses, cytokines and Kaposi's sarcoma.

247. Sequences in the preC region of duck hepatitis B virus affect pregenomic RNA accumulation.

248. Site-specific RNA binding by a hepatitis B virus reverse transcriptase initiates two distinct reactions: RNA packaging and DNA synthesis.

249. Phenotypic mixing between different hepadnavirus nucleocapsid proteins reveals C protein dimerization to be cis preferential.

250. Analysis of the binding of a host cell surface glycoprotein to the preS protein of duck hepatitis B virus.

Catalog

Books, media, physical & digital resources